Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Author Profile and Citation Metrics

OpenAlex identifies Yongyong Yan (ID A5109386566, ORCID 0009-0007-8070-6116) with 31 works, ~918 total citations, and an h-index of 14, with no recorded primary institution. Name disambiguation is a material caveat: multiple similarly named authors appear (e.g., Yongyong Li, h-index 52, 225 works; another Yongyong Yan with 7 works, h-index 3), so identity confidence is moderate and metric attribution carries disambiguation risk. Note the top OpenAlex match for the query string is actually a different researcher (h-index 141), which should not be conflated with this author. An h-index of 14 across 31 works places this author in the productive early-mid career range, likely as a junior PI or senior postdoc in nanomedicine.

Evidence Base: The CaO2@mPDA-SH Nanoplatform Study (2022)

The exemplar publication is a first/corresponding-level contribution to Journal of Nanobiotechnology describing CaO2-loaded mesoporous polydopamine nanoparticles coated with sodium hyaluronate that simultaneously deplete tumor lactate and generate oxygen, reprogramming the immune microenvironment with 72.2% tumor growth inhibition and zero lung metastatic nodules vs ~25 in PBS controls CaO2@mPDA-SH tumor microenvironment nanoplatform study.

The study demonstrates competent multi-technique execution: TEM/DLS/zeta characterization (40.92% CaO2 loading, 147 nm hydrodynamic size), FTIR/XRD confirmation, hemolysis testing (≤5% at ≤200 μg/mL), CCK-8 cytotoxicity (61.7% viability at 200 μg/mL), flow cytometry for immune subsets, and IVIS biodistribution Comprehensive methods and instrumentation in CaO2 nanoparticle study.

Blindspots, Limitations, and Scientific Strength Assessment

Strengths: mechanistic coherence (lactate depletion → HIF-1α/GLUT1/LDHA downregulation → immune reprogramming), a defined falsification criterion, transparent funding disclosure (NSFC 32271387, Tongji Young Hundred-Talent Program), and declared absence of competing financial interests.

Weaknesses (reported and inferred): single tumor model (4T1/BALB/c) limiting generalizability; small n=5 groups limiting statistical power; short-term in vivo evaluation only; no combination with standard-of-care therapy; data available only on request, limiting external replication; the striking 0 vs 25 lung nodule result demands independent confirmation. No human or translational data exist yet.

Confidence note: the assessment rests on one fully extracted paper plus OpenAlex metrics of uncertain disambiguation confidence; a broader publication portfolio would likely raise or lower these estimates. What would change the verdict: replication of the anti-metastatic result in independent labs, multi-model in vivo data, and evidence of sustained citation trajectory beyond 918 citations.

Compare to Nanomedicine PeersDeep Paper Review

 BGPT Author Review

Scientific Quality

An h-index of 14 over 31 works with ~918 citations indicates a competent early-mid career researcher. The exemplar paper shows strong methodological breadth and mechanistic logic, but rests on a single murine model, n=5 groups, short follow-up, and a dramatically clean anti-metastatic result (0 vs 25 nodules) that warrants independent replication. Name disambiguation uncertainty further limits confident assessment.

Communication Quality

The study reports clear, organized structure across characterization, in vitro, and in vivo sections with defined problem statement and falsification criteria. However, quantitative reporting is incomplete in places (several comparisons described only qualitatively as 'increased' or 'lower'), and no raw data repository was provided.

Author Novelty

Combining CaO2-based oxygen generation with lactate depletion in an HA-targeted polydopamine platform to jointly address hypoxia and acidity is a creative multi-mechanism design in an active field, though adjacent lactate-depletion and CaO2 nanosystems were concurrently being explored by other groups.

Scientific Rigor

Appropriate controls (Ca(OH)2@mPDA_SH at 30.23% inhibition isolates the CaO2 oxygen-generation contribution), multiple orthogonal characterization methods, and safety assays are commendable. Deductions for small n=5 groups, single-model design, qualitative-only reporting of several immune markers, request-only data availability, and no blinding statement.